‘We Are Going To Be Deeply Engaged In The Biosimilar Arena’ – Accord BioPharma Sets Out US Strategy
Chrys Kokino, President Of Accord US, Outlines Firm’s Plans For Biosimilars
Hot on the heels of Accord BioPharma recently announcing a US filing for a Stelara biosimilar – as well as a settlement that will let it enter the market in May 2025 – Chrys Kokino, president of Accord US, talks about how the product fits into the firm’s wider biosimilars strategy in the first part of a two-part interview with Generics Bulletin.
